Dracen Pharmaceuticals
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
780 3rd Ave Fl 18, New York City, New Yo...Phone Number
(410) 659-2777Website
www.dracenpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Dracen Pharmaceuticals
Dracen Pharmaceutical is a private company focused on developing innovative cancer treatments by leveraging immuno-metabolism. Their lead candidate, DRP-104, is a glutamine antagonist designed to shrink tumors and enhance the tumor microenvironment for improved immuno-oncology responses. The company targets a range of cancers, particularly those with genetic mutations that make them susceptible to their therapies. Dracen aims to provide effective solutions for patients with advanced solid tumors, addressing significant unmet medical needs.Explore more
Dracen Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dracen Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Dracen Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Dracen Pharmaceuticals
Earning: See what the market has to say on Dracen Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Dracen Pharmaceuticals has new funding data
Product Launch: Get notified when Dracen Pharmaceuticals launches new products
Check out if Dracen Pharmaceuticals is spiking on competitors!
Check if Dracen Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Dracen Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Dracen Pharmaceuticals
Find more new buyers
Compare Similar Companies to Dracen Pharmaceuticals
Compare insights from companies similar to Dracen Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dracen Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Dracen Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Dracen Pharmaceuticals.
Dracen Pharmaceuticals Tech Stack
A closer look at the technologies used by Dracen Pharmaceuticals
See more technologies
Dracen Pharmaceuticals News & Media
Dracen Pharmaceuticals announces publication in Molecular Cancer Therapeutics
Article titled “Sirpiglenastat (DRP-104) Induces Anti-tumor Efficacy Through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate & Adaptive Immune Systems” highlights Dracen’s lead clinical compound (PRWeb October 10, 2022) Read the full story at https://www.prweb.com/releases/2022/10/prweb18944062.htmDracen Pharmaceuticals announces oral presentation at Festival of Biologics World Immunotherapy Congress 2022
Presentation explores the benefits of broadly targeting glutamine metabolism in cancer and provides a clinical development update on Dracen’s sirpiglenastat (DRP-104) (PRWeb March 09, 2022) Read the full story at https://www.prweb.com/releases/dracen_pharmaceuticals_announces_oral_presentation_at_festival_of_biologics_world_immunotherapy_congress_2022/prweb18544215.htmDracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021...
Trial in progress poster: Phase 1 & Phase 2a, first-in-human study (FIH) of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors (PRWeb June 03, 2021) Read the full story at https://www.prweb.com/releases/dracen_announces_drp_104_sirpiglenastat_presentation_at_asco_2021_virtual_annual_meeting/prweb17979847.htmDracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting
Posters further expand on preclinical immuno-oncology mechanism of action and combination therapy with various checkpoint inhibitors and confirm DRP-104 single agent activity in KEAP1 and STK11 mutant lung tumors and head and neck squamous cell carcinoma (PRWeb April 05, 2021) Read the full story at https://www.prweb.com/releases/dracen_announces_drp_104_sirpiglenastat_presentations_at_aacr_virtual_annual_meeting/prweb17839065.htm
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Dracen Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Dracen Pharmaceutical is a private company focused on developing innovative cancer treatments by leveraging immuno-metabolism. Their lead candidate, DRP-104, is a glutamine antagonist designed to shrink tumors and enhance the tumor microenvironment for improved immuno-oncology responses. The company targets a range of cancers, particularly those wi... Read More
